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Background The time between the diagnosis of cancer and a planned definitive
surgical procedure offers a strong and direct approach for assessing the impact of
interventions (including lifestyle interventions) on the biology of the target tissue
and the tumor. Despite the many strengths of presurgical models, there are
practical issues and challenges that arise when using this approach.
Purpose/Methods We recently completed an NIH-funded phase II trial that utilized
a presurgical model in testing the comparative effects of flaxseed supplementation
and/or dietary fat restriction on the biology and biomarkers associated with
prostatic carcinoma. Herein, we report the rationale for our original design, discuss
modifications in strategy, and relay experiences in implementing this trial related to
the following topics: (1) subject accrual; (2) subject retention; (3) intervention
delivery; and (4) retrieval and completion rates regarding the collection of paraffin-
embedded and fresh frozen prostate tissue, blood, urine, ejaculate, anthropometric
measures and survey data.
Results This trial achieved its accrual target, i.e., a racially-representative
(70% white, 30% minority) sample of 161 participants, low rates of attrition
(7%); and collection rates that exceeded 90% for almost all biospecimens and
survey data. While the experience gained from pilot studies was invaluable in
designing this trial, the complexity introduced by the collection of several
biospecimens, inclusion of a team of pathologists (to provide validated readings),
and shifts in practice patterns related to prostatectomy, made it necessary to revise
our protocol; lessons from our experiences are offered within this article.
Conclusions While our experience specifically relates to the implementation
of a presurgical model-based trial in prostate cancer aimed at testing flaxseed-
supplemented and fat-restricted diets, many of the lessons learned have broad
application to trials that utilize a presurgical model or dietary modification within
various cancer populations. Clinical Trials 2008; 5: 262–272. http://
ctj.sagepub.com
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Lifestyle factors are postulated to play a key role
in the development and progression of prostate
cancer (PC) [1,2]. Diet is presumed to play an
especially strong role, yet the evidence base for
undertaking dietary change with the intent of
cancer prevention or control is lacking. To date,
much of what is known about diet and PC comes
from epidemiologic investigations that are limited
in their ability to show cause and effect, in vitro
studies or interventions in animal models which
may or may not have relevance to the disease
course in humans, or small clinical pilot studies
that lack adequate control or that rely on indirect
endpoints of disease (e.g., prostate specific antigen
[PSA])[2]. Hence, we look to large-scale randomized
controlled trials (RCT), such as the Selenium and
Vitamin E Cancer Prevention Trial (SELECT) [3], to
provide us with convincing evidence that dietary
factors do indeed make a difference; however, these
trials are both time- and resource-intensive [4,5].
The presurgical model has been proposed as an
efficient means of assessing the impact of various
interventions on PC [6]; this model also can be
applied to studies of dietary factors. The purpose of
this article is to describe the original design, shifts
in strategy and the lessons learned while imple-
menting an NIH-funded (R01 CA85740) phase II
RCT that utilized the presurgical model to
compare the effects of dietary fat restriction and/
or flaxseed supplementation on PC and its asso-
ciated biomarkers.
Background
The presurgical or preoperative model has been
proposed to evaluate a wide spectrum of interven-
tions in various site-specific cancers [6]. In PC, it
has experienced limited use, though recently a
small study was reported that assessed changes in
serum proteomic patterns with pre-surgical vitamin
E and selenium supplements as a subproject of the
SELECT trial [7]. In that 2 2 placebo-controlled
study, 48 PC patients were randomly assigned to
receive vitamin E and/or selenium during the 3–6
weeks prior to prostatectomy, and the proteomic
patterns of their sera collected at baseline were
compared to those of sera after treatment. That
protocol differs from typical presurgical designs
where survey data and most biological samples
(blood, urine, semen, etc.) are collected at baseline
and just prior to surgery, but where excised tumor
also is assessed for relevant endpoints. This more
complete use of the presurgical model was used in
our phase II RCT.
Our exploration of the potential benefits of
dietary manipulation began with an incident case
of a patient with high grade prostatic intraepithelial
neoplasia (HGPIN) who demonstrated remarkable
reductions in PSA and notable cellular atrophy
upon repeat biopsy after adhering to a flaxseed-
supplemented, low-fat diet. Given that flaxseed is
an exceptionally rich source of both dietary lignans
and omega-3 fatty acids, dietary factors that have
been found to influence androgen and COX-2
metabolism (the effects on the COX-2 pathway
may be further enhanced by a low-fat diet which
may accelerate the conversion of alpha-linolenic
acid [ALA : 18 : 3n-3] to longer chained and more
physiologically active omega-3 fatty acids, eicosa-
pentanoic [EPA : 20 : 5n-3] and docosahexanoic
[DHA : 22 : 5n-3] acids)[8–14], we followed-up this
observation with three studies: (1) an in vitro
experiment that exposed three major PC cell lines
(LNCaP, DU-145, and PC-3) to flaxseed-derived
mammalian lignans [15]; (2) an animal feeding
experiment that tested a 5% flaxseed-supplemented
diet against an isocaloric-controlled diet in trans-
genic mice genetically programmed to develop PC
[16]; and (3) a pilot feasibility study of a low-fat,
flaxseed-supplemented diet in men found to have
HGPIN or atypia [17]. In all of these studies,
flaxseed derived lignans, flaxseed itself or the
flaxseed diet with concomitant dietary fat restric-
tion were found to significantly hinder prostatic
growth (via decreased proliferation and increased
apoptosis in both malignant and benign tissue),
and/or reduce tumor burden.
While our original plan was to test flaxseed
supplementation and dietary fat restriction in men
with HGPIN [18], the experience gained from our
feasibility study suggested that this would be an
unfruitful strategy for several reasons: (1) there is
poor inter-rater concordance regarding the classifi-
cation of HGPIN between pathologists [19]; (2) the
diagnosis of HGPIN is relatively rare without
co-occurring PC [20], making recruitment difficult;
and (3) HGPIN is often absent upon rebiopsy [17].
The possibility of using a presurgical model [6] in PC
patients was intriguing but we were concerned
about the effect of a dietary modification on the
biologyoftheprostateifonlyimplementedforafew
weeks. While theoretically the presurgical model
could be undertaken for a much longer length of
time, i.e., months or even years, this is not a feasible
option for PC patients, who are anxious about their
disease and unlikely to postpone their treatment.
Thus, we conducted a pilot study to test the
feasibility of the presurgical model by enrolling 25
men scheduled for prostatectomy, who followed a
flaxseed-supplemented, low-fat diet [21]. Accrual to
the study was much more rapid than that of the
previous HGPIN study [17], and study subjects were
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days) during which time they experienced signifi-
cant decreases in serum testosterone, cholesterol
and free androgen index. Anonsignificant (p¼0.10)
reduction in PSA also was observed among the
subset of patients with Gleason sum 6 or less disease.
Most compelling, however, was that compared to
historic controls matched on age, race, PSA at
diagnosis and biopsy Gleason sum, men on the
diet had tumors with significantly lower prolifera-
tion rates and higher rates of apoptosis. Thus, the
presurgical model appeared to offer a feasible means
to test our dietary intervention and we used this
body of research to justify a phase II trial to test
the comparative effects of flaxseed-supplementa-
tion and/or dietary fat restriction on PC.
Methods and design considerations
Design
Given that our pilot studies combined flaxseed
supplementation with dietary fat restriction, there
was a need to disentangle potential effects of each.
One possible design, often used in similar settings,
involves comparing the effects of treatment inter-
ventions on the change from baseline. In our
setting, this would involve the difference between
the result from the diagnostic biopsy and the result
fromthesurgicalspecimen(i.e.,usingthe‘patientas
his own control’). However, unless a ‘no treatment’
control group is included, the substantial hetero-
geneity within the target (prostate gland in our case)
and the very limited sampling of the target in the
original biopsy could lead to biased results. Thus, we
employed a 2 2 factorial design [22] with a no
treatmentcontrolgroupandoutcomesmeasuredon
each subject at the end of the treatment period. The
treatments were defined through the presence or
absence of the two factors, flaxseed supplementa-
tion and dietary fat restriction, defining the
following four treatments: (1) control; (2) flaxseed-
supplemented diet (FS); (3) low-fat diet (LF); and
(4) flaxseed-supplemented, low-fat diet (FSLF). It
also would have been desirable to utilize placebo
controls, but this was not feasible either for flaxseed
supplementation or for the low-fat diet. Unlike
micronutrient supplementation trials that rely on
small dosages and which lend themselves to
a placebo-controlled design, the 30g. daily dose
flaxseed tested was substantial and nonamenable to
a suitable placebo, since other fibers, even cellulose,
have been shown to affect hormonal levels [23].
Also,for obviousreasons, itwasnotpossible toblind
low-fat diet conditions. Therefore, in this single-
blinded study, we attempted to reduce potential
contamination of the control group through the
following strategies: (1) emphasizing the impor-
tance of control group participation among men
assigned to this arm; (2) offering men results of their
dietary analysis and guidance to improve their
diets once they had recovered from their surgery;
(3) administering a detailed food frequency
questionnaire at both baseline and follow-up from
which data could be used to control for unplanned
dietary change; and (4) assessing biomarkers
associated with a low fat diet (serum lipids) and
flaxseed consumption (urinary lignan metabolites),
which also could be used to assess the potential for
contamination and confounding.
Endpoints
We originally considered PSA velocity as the
primary endpoint in the study but PSA is influ-
enced by a myriad of factors and may not
necessarily reflect the status of the cancer. Thus
tumor proliferation rate, as assessed by murine
hybridoma (MIB-1) staining of the prostatectomy
specimens was selected as our primary endpoint,
since it was used successfully in our previous
studies. The MIB-1 marker (also known as k:-67)
also has validated use in nutrition intervention
trials [24], and has been endorsed by the Prostate
Cancer Chemoprevention Trial Consensus Panel
as an accurate and reproducible measure [25].
While apoptosis, as assessed by terminal deoxynu-
cleotidyl transferase (TdT)-mediated dUTP- nick
end-labeling (TUNEL), also was considered, the
fact that we did not observe adequate variation
within our pilot studies caused us to relegate this to
a secondary endpoint. The specific aims of the
study were to determine differences between the
four study arms with respect to the following: (1)
tumor proliferation as assessed by MIB-1 staining of
prostatectomy specimens (primary aim), as well as
rates of apoptosis using TUNEL (secondary aim); (2)
changes in biomarkers that reflect or are associated
with PC growth and/or are influenced by a low-
fat diet or flaxseed supplementation, such as
serum PSA, total testosterone, sex hormone binding
globulin (SHBG), insulin-like growth factor (IGF-1),
IGF binding protein-3 (IGFBP-3), c-reactive
protein (CRP), and serum lipids (secondary aim)
[21,26–29]; (3) changes in nutritional biomarkers
(i.e., levels of lignans in the urine and seminal fluid,
and fatty acid profiles of circulating erythrocytes
and prostatic tissue); and (4) to explore associations
between dietary change, change in dietary biomar-
kers, change in hormonal intermediates, and
change in study endpoints (secondary aim).
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We tested the null hypothesis H0:0¼1 against
the two-sided alternative H1:06¼1 where  (i¼0
for ‘control’, i¼1 for FS or LF) was the mean
logarithm of the MIB-1 proliferation index and
used two primary tests, one for FS and one for LF.
Our preliminary studies suggested that the com-
bination of FS and LF resulted in log proliferation
rates that were on average 33% lower than the
log proliferation rates observed among control
subjects. This translated into an observed effect
size of approximately 0.56. Given some hesitation
in relying solely upon an effect size from a
study which employed historic controls, we also
banked on the findings of Hamalainen et al. who
also found a similar effect size in a fiber-supplement
trial aimed at testosterone reduction [30]. To
achieve a statistical power of 0.80 (two-sided test,
¼0.05) at an effect size of 0.50, a total of 128
participants (32 per cell) was needed. An additional
eight participants per cell was added to cover losses
due to drop-out (4% attrition in the pilot study)
and to allow for a slight negative interaction [31].
Thus, the total target sample size was 160 patients
(40 in each cell).
Eligibility
Inclusion and exclusion eligibility criteria are listed
in Table 1; most exclusionary criteria were insti-
tuted to reduce potential confounding.
Accrual
PC patients were recruited from the urology clinics
at Duke University Medical Center (DUMC),
the Durham Veteran’s Administration Medical
Center (DVAMC), and five sites associated with the
University of Michigan Cooperative Community
Oncology Program (CCOP) Research Base. Written
consent was obtained using two different methods
depending on the study site IRB requirements and
convenience for the patient. In most cases, patients
were initially contacted by telephone, the study was
explained and interest in the study was elicited.
Patients who were not interested were thanked for
their time and then asked to volunteer their reasons
for disinterest; this information was de-identified
and recorded. Patients who expressed an interest
were screened for eligibility, and reasons for ineligi-
bilityalsoweretrackedinadeidentifieddatabase.To
help defray costs associated with study participation
and reduce potential barriers to accrual, men were
offered a monetary incentive of $100 if they
completed the study.
Men who were both eligible and interested in
participating were either asked to report for a pre-
baseline appointment (where written consent was
obtained and men weregiven surveys to complete at
home, as well as containers [coolers and ice packs]
and instructions to collect a 24-h urine sample and
anejaculatesampleorwereexpressmailedaconsent
form, surveys and directions and containers for
specimen collection. In either case, written consent
was obtained prior to the collection of specimens.
Written consent was obtained for the study itself
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
  Men with pathologically confirmed prostate cancer who
elected prostatectomy as their primary initial treatment
  Men who had received hormonal or neo-adjuvant
chemotherapy
  Men who were scheduled for prostatectomy at one of the
participating study sites and who were at least 21 days from
surgery
  Mentally-competent, English-speaking and -writing men with
  Men currently adhering to a low fat diet (the 16-item NCI
Percent Energy from Fat Screener was programmed into
Microsoft Excel and used in real-time to screen-out men
whose diets were  30% of energy from fat) [27].
telephone access (interventions and evaluative surveys were
based in English and relied on written materials and
telephone counseling)
  Men currently consuming flaxseed
  Men who would be taking antibiotics within the study period
(antibiotic-use inhibits the intestinal conversion of flaxseed
lignans to mammalian-based lignans [40].
  Men taking dietary supplements that were newly started or
who planned to initiate use during the study period. At the
origin of the study, the definition for ‘‘newly started dietary
supplement’’ encompassed ‘‘any dietary supplement initiated
within 6-months,’’ this definition was revised soon after
launching into the field when it became clear that we were
excluding a very high proportion of men; our revised criterion
excluded those who started dietary supplements [not includ-
ing standard multi-vitamin preparations] within the past 3
months.
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to utilize any unused biospecimens, as well as to
assess the whole blood sample for DNA once
definitive genes for PC were identified. All men
were asked to report for both the baseline and
follow-up appointments after a 12-h fast; follow-up
appointments were scheduled within 3-days of
surgery. To reduce the variation associated with
diurnal fluctuation with some of the endpoints
(e.g., testosterone), baseline and follow-up appoint-
ments werescheduled in themorning. Additionally,
because PSA may be influenced by prostatic
manipulation, baseline appointments were sched-
uled at least 14 days post-biopsy and at least 3 days
post-digital rectal exam [32].
Baseline appointment and measures
Bloodwasdrawnviavenipunctureandeitherkeptas
whole blood or configured into sera and plasma.
Samples were aliquotted and stored at  70 C until
completion of the study, whereupon they were
batch-analyzed via immunochemiluminometric
assay (LabCorp, Inc., Burlington, NC) for PSA, total
testosterone, SHBG, total and low density choles-
terol, CRP, IGF-1, and IGFBP-3. Erythrocyte mem-
branes also were isolated, stored and batch-analyzed
upon study completion via capillary gas chromato-
graphy (GC) to discern fatty acid composition [33].
Start and stop times for 24-h urine collections
were recorded, and samples (which arrived chilled
in coolers) were measured for volume, mixed,
and aliquotted. One aliquot was immediately
analyzed for creatinine using kinetic methods
(DUMC Clinical Laboratories and LabCorp, Inc,
Burlington, NC) to assure a 24h collection and to
use as a benchmark for expressing lignan excretion
(a marker of dietary adherence to the flaxseed-
supplemented regimen); urinary lignans were
quantified using high performance liquid chroma-
tography(HPLC)[34,35].Similarmethodswereused
to chronicle ejaculate collection and to analyze the
lignan content of seminal fluid [34,35]. As with
urine, converted plant-lignans are expressed in the
seminal fluid, and findings of Morton et al. suggest a
reduced risk of PC not only among men, who
consume higher amounts of dietary lignans, but
who also express higher concentrations of lignans
in their seminal fluid [11,34].
Given increasing evidence that body weight
affects the progression of prostatic carcinoma and
may confound study findings [36], men were
measured for height using a wall-mounted
stadiometer and measured for weight using a
routinely-calibrated digital scale; body mass index
(BMI) was derived using the formula kg/m
2.
Given a need to control for other dietary factors
(lycopene, vitamin E, etc.) and physical activity,
men also were asked to complete the Diet History
Food Frequency Questionnaire (modified to include
regionally-consumed foods, such as okra, hominy,
grits, and various organ meats)[37,38], and the
Aerobics Center Longitudinal Study Physical
Activity Questionnaire [39]. Information regarding
various socio-demographic factors, medical history,
prescribed and over-the-counter medications and
supplements also was recorded.
Randomization
After all baseline data and biospecimens were
collected (the exception being ejaculate which
several men either refused or were unable to
provide),menwereblockrandomizedonprognostic
factors of race (black vs. non-black) and biopsy
Gleason sum (<7 vs. 7þ) [1], to one of four treat-
ment arms: (1) control; (2) flaxseed-supplemented
diet; (3)low-fatdiet; and(4)flaxseed-supplemented,
low-fat diet. The randomization process was
designed and carried out by the biostatistics group
in the Duke Comprehensive Cancer Center. While
the treatment arms differed with regard to dietary
regimen, men in all arms were contacted weekly by
the study staff to maintain contact (this was
especially important since surgeries often were
rescheduled) and to assess and reinforce adhe-
rence, and to answer any diet-related questions.
Additionally, wives of participants (or partners
responsible for food procurement or preparation)
were encouraged to attend the baseline appoint-
ment to enhance the quality of dietary instruction
should men be randomized to one of the modified
diet arms.
Control arm
Men in this arm were asked to continue their usual
diet and not to make any changes in their dietary
intake.
Flaxseed-supplemented (FS) arm
Men assigned to this arm were provided with ample
ground flaxseed to last until their date of surgery.
To reduce the variability in nutrient composition
that could occur between crops, the flaxseed used
for this study was obtained from ENRECO, Inc.
(Manitowoc, WI) in one lot (150kg), and was
analyzed for nutrient content at two time points
during the study period. Given its propensity for
rancidity[40],theflaxseed wasstoredinwholegrain
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in daily dose (30g) sealed opaque packets as needed
(note that flaxseed must be ground, or the hull split,
in order to enhance the absorption of its omega-3
fatty acids and lignans). Starter kits with stepped
doses were provided, such that for days 1–3, packets
contained only 10g of ground flaxseed, for days 4–6
packets contained 20g of flaxseed, and by day 7 the
full 30g dose was provided. This stepped dose
approach was considered necessary given the
considerable fiber load that flaxseed imposes on
the gut ( 9g/30g dose), and the propensity for
gastrointestinal discomfort if initiated in full-dose
fashion. Men receiving flaxseed also were instructed
to drink at least 64oz. of fluids/day to reduce any
potential risk of colonic impaction or dehydration
resulting from the increased fiber load [41], and to
keep their flaxseed packets under refrigeration
(to reduce spoilage). In addition, participants in
this arm were provided with logs to record their
daily intakes of flaxseed to the nearest quarter of a
packet, and to return any unused packets at the
time of their follow-up appointment. These
procedures were adapted from pill counts which
have been found to provide a valid measure of
adherence in pharmacologic trials (including fiber
supplement trials)[41,42].
Low-fat arm (LF)
Men randomized to this arm were instructed by
registered dietitians on a diet containing  20% of
total energy from dietary fat. Fat gram ‘budgets’
were individually calculated for each participant
using the following formula: ideal body weight
(lb) 15 0.2kcal from fat/9kcal/gram. Men were
provided with fat gram counters and asked to record
all foods consumed along with the corresponding
number of fat grams, and to tally the number of fat
grams consumed each day. Participants also
received written and verbal instruction on meal
planning, food preparation, shopping, and dining.
Flaxseed-supplemented, low-fat diet (FSLF) arm
Men in this arm received instruction and supplies
for both of the diet regimens described above.
Follow-up appointment and measures
Within three days of surgery, and most often on the
morning of surgery, participants reported for the
follow-up appointment. At this time, participants
were asked to report any changes in health status
and/or new medications, and all measures (except
height) performed during the baseline appointment
were repeated. Additionally, all participants were
asked to complete CALGB toxicity index scales for
potentially relevant side effects, i.e., nausea, vomit-
ing, diarrhea, impotence/libido, and allergy [43].
Men assigned to diet modified arms also were asked
to rate their adherence to the FS (average number of
days/week flaxseed was consumed and the average
amount) and/or LF diets (average number of days/
week they adhered to fat gram budgets). These
adherence measures served as yet another measure
of dietary intake, in addition to the DHQ, record
logs, and biomarkers (i.e., urinary lignans).
Upon prostatectomy, fresh, frozen tissue was
retrieved from two defined regions in the central
and peripheral zones of the prostate using a 3mm
punch biopsy instrument. These defined regions
for biopsy were selected based on the following
rationale:(1) samples would be extracted from the
interior prostate and therefore would not interfere
with surgical margin assessment; and (2) zones
slated for harvest had a lower probability of
including tumor and therefore less likely to be
needed for patients’ clinical work-ups. Each of the
two tissue samples was flash frozen in liquid
nitrogen, placed in individual cryovials and stored
at  70 C until completion of the study. It should
noted that the prostatectomy tissue harvested at
any of the CCOP sites remained on-site until the
full clinical work-up for each patient was complete,
just in case the extracted sample was needed for
clinical assessment. Once released, the sample was
shipped on dry ice to the CCOP coordinating
center and then onto DUMC. At completion of
the study, prostate tissue homogenates were batch-
analyzed via GC to discern fatty acid composition
using methods described previously.
The primary study pathologist (RV) reviewed
clinical pathology reports and slides for each case
and determined the blocks that should be cut and
preparedfordeterminationofproliferation(primary
endpoint) and apoptosis in both tumor and benign
tissue. Proliferation rates were assessed using anti-
body from the MIB-1 clone at a dilution of 1:200
(Biocare, Walnut Creek, CA) [24]. Prepared slides
were independently reviewed by both the primary
study pathologist (RV) and the secondary study
pathologist (JFM) who were blinded with regard to
study arm, using the following method: (1) at low
magnification a random starting point in the tumor
was chosen; and (2) then at high magnification, an
average of 547 sequentially-encountered tumor cell
nuclei were evaluated for MIB-1 positivity (range
110–2550). The result was reported as the ratio of
positive nuclei divided by the total number evalu-
ated. Values obtained from the two pathologists
were then averaged and mean values used in
Presurgical prostate cancer diet trial 267
http://ctj.sagepub.com Clinical Trials 2008; 5: 262–272statistical calculations. The degree of apoptosis was
measured using TUNEL [44]. Labeled nuclei were
assessed by the two study pathologists using the
methods described above and under fluorescence
microscopy. Slides were given a rank score of 0
(lowest apoptotic index), 1 or 2 (highest apoptotic
index), and averaged values were used in statistical
analyses.
Statistical analysis
A pre-planned interim analysis was pursued
(at a nominal significance level of 0.001) after 50%
of the subjects had been enrolled. At that time,
results indicated that the null hypothesis could not
be rejected and accrual continued until the target
sample size was achieved. Data collection for the
trial is now complete and data analyses are under-
way. Statistical regression techniques were used to
analyze the effect of variables such as race, age,
biopsy Gleason sum, weight loss, exercise, dietary
fat and lignan intakes, and physiologic markers
associated with dietary modification (i.e., concen-
trations of lignan in the prostatic fluid, prostatic
tissue, and the urine and lipid composition of the
prostate) on hormonal intermediates (i.e., androgen
levels, IGF-1 and IGFBP-3), and ultimately on study
endpoints (i.e., rates of proliferation and apoptosis
and PSA change). Secondary analyses explored
whether the results differed among men who were
upgraded upon surgery (i.e., those whose surgical
Gleason sums exceeded those at biopsy, which may
be a particular issue among men who have Gleason
sums of 6 or less at biopsy and then transition to
higher scores upon surgery) [45]. Thus, biopsy may
have misclassified men who would have otherwise
been stratified differently.
Conduct of the study/overcoming barriers to
completion
This study accrued patients from July 5, 2002 to
April 17, 2006, and the recruitment index (number
of days to accrue one analyzable study subject) was
8.9 days [46]. This differed from original projections
which assumed a recruitment index of  6.8 days
and proposed a 3-year window to achieve targeted
accrual. Furthermore, at the time this study was
conceived (2000), we assumed that accrual could be
achieved solely with the clinic loads available at
DUMC and DVAMC, relying on surgical case loads
that approximated 300 cases/year. Months into the
trial, it became apparent that this strategy was
flawed due to higher than anticipated numbers of
men who opted for treatments other than
prostatectomy (a treatment trend that also resulted
in a decreased wait-time prior to prostatectomy).
Newly armed with knowledge that the proportion
of patients eligible for this presurgical trial was
significantly lower in this age of expanding treat-
ment options, we forged a collaboration with the
UniversityofMichigan-CCOPtoexpandourrecruit-
menteffort.Amongallsitesatotalof1090menwere
actively screened for this trial and 161 were
ultimately enrolled (Figure 1). Roughly 48% of
actively screened subjects were ineligible with
leading reasons for ineligibility being: (1) opting
for treatment other than surgery or undecided
regarding treatment choice; (2) scheduled for sur-
gery within 21 days; (3) dietary exclusions; and
(4) receiving neoadjuvant treatment. A refusal rate
of  38% also was observed with leading reasons for
refusal being: (1) general disinterest or no expressed
reason, (2) lack of time; and (3) transportation
concerns. Time and travel issues are common
reasons for nonparticipation in clinical trials, thus
such findings were anticipated. Under other reasons
for refusal, a substantive proportion of men voiced
discomfort in collecting 24-h urine and ejaculate
samples, and although we discontinued the require-
menttoprovidethelattersample(since itwasonlya
secondary endpoint and a noted barrier to accrual)
these study procedures may have been off-putting,
not only for those who specified the reason for their
refusal, but also those who expressed general
disinterest with no stated reason.
Table 2 provides demographic characteristics of
the study sample. Data suggest the accrual of a
diverse sample that was racially representative of
the population from which it was ascertained.
Given the difficulties reported regarding minority
recruitment to clinical trials, it is clear that this trial
serves as a success [47]. This achievement may have
been due to the use of a monetary incentive and the
efforts of the study staff to piggyback both baseline
and follow-up appointments onto existing clinic
appointments. While the age of study participants
was roughly a decade younger than the mean age
reported for the onset of PC [48], it must be
remembered that this sample was extracted from a
population scheduled for surgery and notably
younger.
Baseline appointments, randomization and
weekly contact proceeded smoothly and asplanned.
As the study progressed, higher percentages of
men preferred to be contacted via email than by
telephone, and this helped conserve study staff time
and resources. Only one adverse event was reported
throughout the course of study implementation:
one study participant stood-up suddenly, lost
consciousness and suffered a nonsevere head
injury (but one that required an emergency room
visit). This event was not considered diet-related.
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with 10-of-12drop-outs discontinuing the study
because they subsequently decided against surgery.
In such cases, we attempted to schedule follow-up
appointments to collect biospecimens and surveys
that would be useful in secondary analysis;
however, this was not always possible since some
men refused to travel if no longer scheduled
for treatment. Reasons for the two other drop-outs
also involved prostatectomy, in one case the
participant’s surgery was moved-up by three
weeks and in another, the subject’s surgery was
delayed by many months and the participant did
not want to adhere to a low-fat diet for an extended
period of time. No socio-demographic differences
were observed between drop-outs and study
completers.
This trial was exceptionally complex with regard
to sample and data collection. Success rates regard-
ing specimen retrieval and data collection among
the primary study site (DUMC/DVAMC) and CCOP
sites are reported in Table 3. Retrieval of paraffin-
embedded tissue for MIB-1 analysis (primary
endpoint) as well as TUNEL was 100%. The
collection of fresh frozen tissue achieved lower
retrieval rates of 89–96%, likely owing to the fact
that this is a time-sensitive and nonstandard
procedure. In cases where tissue was not success-
fully retrieved, it always involved a breakdown in
communications between the study staff and
personnel of the pathology laboratory who forma-
lin-fixed the prostatectomy specimens before cores
of fresh tissue could be harvested. Collection of
1090 Prostate Cancer Cases
Ascertained 
161  Randomized
929 Excluded 
     447 Ineligible (125 were scheduled for surgery within 21 days; 
114 opted for other treatment, 89 had dietary exclusions
(33 already adhered to a low fat diet, 27 had newly started
dietary supplements, 17 were consuming flaxseed and
another was following a structured diet); 60 were receiving
neoadjuvant treatment; 40 were unsure and 19 were had
other concerns).
     354 Refusals (104 had no interest; 63 reported lack of time; 57
reported travel concerns; 31 stated that it was “too much” at
current time; 7 had other concerns and 92 specified no
reason)
     108 No response
         3 Unusable address
       17 Other 
41 Assigned to the control:
To continue usual diet
40 Assigned to flaxseed 
supplement diet (FS):
30 g. ground flaxseed/day
40 Assigned to low-fat diet
(LFD):
Diet with <20% of energy
from fat
40 Assigned to FSLFD:
Diet with 30 g. ground
flaxseed/day and <20% of
energy from fat
2 Lost-to-follow-up
- 2 cancelled prostatectomy
1 Lost-to-Follow-up  
- 1 cancelled prostatectomy
5 Lost-to-follow-up  
- 4 cancelled prostatectomy
- 1 surgery date moved-up
4 Lost-to-follow-up  
- 3 cancelled prostatectomy
- 1 refused to continue LF
   after surgery was delayed
   for several months
41 Included in
Intention-to-treat analysis
40 Included in  
Intention-to-treat analysis 
40 Included in
Intention-to-treat analysis
40 Included in
Intention-to-treat analysis
Figure 1 Study flow diagram
Table 2 Characteristics of the study sample
Total
Age (years)
Mean (SD) 59.2 (7.3)
Range 36–73
Race – % (n)
White 70% (112)
African American 26% (42)
Other 4% (7)
Education – % (n)
<High School/unknown 9% (15)
High School Grad/GED 20% (32)
Some College/Trade 29% (46)
College Grad/Post-grad 42% (68)
Biopsy Gleason Sum – % (n)
<7 68% (110)
7þ 32% (51)
Presurgical prostate cancer diet trial 269
http://ctj.sagepub.com Clinical Trials 2008; 5: 262–272blood, urine, anthropometric measures and survey
data also was highly successful with rates generally
surpassing 90%. Indeed, the primary problem
regarding sample retrieval related specifically to
the collection of ejaculate, where rates were notably
low among the primary study site (58% at baseline/
39% at follow-up) and even lower at CCOP sites
(24% at baseline/18% at follow-up). While the
study protocol originally called for extraction of
seminal fluid via prostatic massage, this technique
was abandoned for two reasons: (1) poor success
in obtaining ample fluid from older men who were
likely to comprise our study sample; and (2)
concern that this procedure would impose a
considerable barrier to recruitment. It is unknown
if our poor success rate in obtaining ejaculate could
be overcome by other methods or if this is an
inherent issue in this population. It is noteworthy
that collection rates decreased significantly at
follow-up and could have resulted from the fact
that many follow-up appointments were scheduled
on the day of surgery (when increased anxiety may
have interfered with collection).
Summary
PC trials that employ presurgical models have
several strengths and can ultimately measure the
impact of interventions directly on the target tissue.
While this model provides scientific rigor, it is
balanced by several pragmatic obstacles – obstacles
that are heightened by the diversification of treat-
ment and the many therapeutic options available
to men with this disease. Indeed, we were able to
overcome numerous barriers in implementing this
phaseIIdietarytrialwhichemployedthepresurgical
model. We successfully recruited and retained a
diverse study sample, effectively delivered the
experimental interventions, and retrieved a major-
ity of biospecimens and completed data collection
instruments. Our strategies and methods may assist
others who contemplate chemoprevention studies
that utilize presurgical models not only in PC, but
also cancers of the breast, cervix, head and neck,
bladder, and colon.
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Table 3 Record of successful specimen retrieval or survey/measure completion
Baseline Follow-up
DUMC/DVAMC CCOP DUMC/DVAMC CCOP
Paraffin-embedded tissue 121/121 28/28
Fresh frozen tissue 116/121 25/28
Blood samples
8.5cc serum separator tube 132/132 29/29 126/126 28/28
2–5cc lithium heparin tubes 132/132 29/29 125/126 28/28
3cc EDTA-treated tube 132/132 29/29 126/126 27/28
24-h urine collection 131/132 29/29 124/126 28/28
Ejaculate sample 77/132 7/29 49/126 5/28
Measured height 132/132 29/29
Measured weight 132/132 29/29 126/126 28/28
Completed diet history questionnaire 129/132 26/29 123/126 26/28
Completed physical activity survey 132/132 28/29 123/126 28/28
Completed Logs
fat grams 59/59 15/15
flaxseed 59/59 18/18
CALGB toxicity index 123/126 28/28
Diet self-assessment 91/92 24/28
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